|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...7891011121314151617...4041» |
- dalfampridine / Generic mfg.
Trial primary completion date: Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients (clinicaltrials.gov) - Aug 21, 2015
P4, N=50, Recruiting, Sponsor: Clinique Neuro-Outaouais
Trial primary completion date: Jul 2015 --> Dec 2015
- Trial completion, Trial primary completion date, Surgery: The Comparison of Cataract Lasers Using the Optimedica Catalys Laser and the Alcon LenSx Laser. (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=45, Completed, Sponsor: Steve H. Linn, OD
Trial primary completion date: Jul 2015 --> Dec 2015 Recruiting --> Completed | Trial primary completion date: Aug 2013 --> Dec 2013
- Trial completion, Enrollment change, Trial primary completion date: Melatonin in Relapsing-Remitting Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 15, 2015
P2, N=25, Completed, Sponsor: Tehran University of Medical Sciences
Recruiting --> Completed | Trial primary completion date: Aug 2013 --> Dec 2013 Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Jan 2013 --> Jan 2014
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion, Enrollment change, Trial primary completion date: ALS-TOX: Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea (clinicaltrials.gov) - Aug 14, 2015
P2, N=18, Completed, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Jan 2013 --> Jan 2014 Recruiting --> Completed | N=90 --> 18 | Trial primary completion date: Aug 2015 --> Mar 2014
- Enrollment change: PLACATE-MS: Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS (clinicaltrials.gov) - Aug 14, 2015
P2, N=9, Terminated, Sponsor: University of Rochester
Recruiting --> Completed | N=90 --> 18 | Trial primary completion date: Aug 2015 --> Mar 2014 N=20 --> 9
- Rituxan (rituximab) / Roche
Trial primary completion date: Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Aug 14, 2015
P2, N=74, Active, not recruiting, Sponsor: Lee, Stephanie
N=20 --> 9 Trial primary completion date: Mar 2015 --> Dec 2014
- || Trial primary completion date: Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis (clinicaltrials.gov) - Aug 14, 2015
P2, N=158, Recruiting, Sponsor: University of Miami
Trial primary completion date: Mar 2015 --> Dec 2014 Trial primary completion date: Aug 2015 --> Dec 2016
- Trial primary completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Aug 14, 2015
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Aug 2015 --> Dec 2016 Trial primary completion date: Feb 2015 --> Jan 2016
- Trial completion: Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=30, Completed, Sponsor: Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Trial primary completion date: Feb 2015 --> Jan 2016 Active, not recruiting --> Completed
- || Enrollment closed: REACTIV: Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=75, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
Trial completion: Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) (clinicaltrials.gov) - Aug 12, 2015
P2, N=50, Completed, Sponsor: Mustafa Sahin
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment change, Trial withdrawal: Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 12, 2015
P2, N=0, Withdrawn, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed N=20 --> 0 | Recruiting --> Withdrawn
- ||| Betaseron (IFN-β-1b) / Bayer
Enrollment change: BENEFIT 11: Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis (clinicaltrials.gov) - Aug 12, 2015
P4, N=278, Completed, Sponsor: Bayer
N=20 --> 0 | Recruiting --> Withdrawn N=365 --> 278
- ||| Enrollment closed: Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 12, 2015
P1/2, N=100, Active, not recruiting, Sponsor: University of British Columbia
N=365 --> 278 Recruiting --> Active, not recruiting
- Enrollment closed: Acupuncture or MBSR for Patients With Fatigue and MS (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=141, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| plovamer (CO-14) / EMD Serono
Trial completion: EMR200575-001: Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) (clinicaltrials.gov) - Aug 11, 2015
P2, N=255, Completed, Sponsor: EMD Serono
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed: Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=400, Active, not recruiting, Sponsor: Biogen
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- | NurOwn (MSC-NTF) / BrainStorm Cell Therap
Enrollment closed: NurOwn: Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS (clinicaltrials.gov) - Aug 11, 2015
P2, N=48, Active, not recruiting, Sponsor: Brainstorm-Cell Therapeutics
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: ANSG: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS (clinicaltrials.gov) - Aug 11, 2015
P4, N=30, Completed, Sponsor: Jochen Vehoff
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment closed: IMMUNOSEP: Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 26, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion: Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography (clinicaltrials.gov) - Jul 22, 2015
P=N/A, N=20, Completed, Sponsor: Skulpt, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change, Trial termination: BiobankII: Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 22, 2015
P4, N=8, Terminated, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Completed N=250 --> 8 | Recruiting --> Terminated; lack of recruitment
- Campath (alemtuzumab) / Sanofi
Enrollment change, Trial termination, Trial primary completion date: Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases (clinicaltrials.gov) - Jul 22, 2015
P1, N=4, Terminated, Sponsor: Duke University
N=250 --> 8 | Recruiting --> Terminated; lack of recruitment N=20 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jul 2015; low accrual
- Trial primary completion date: Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=125, Active, not recruiting, Sponsor: University Hospital, Montpellier
N=20 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jul 2015; low accrual Trial primary completion date: May 2015 --> Feb 2014
- Biomarker, Enrollment change, Trial termination, Trial primary completion date: CYTOSEP: Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=101, Terminated, Sponsor: University Hospital, Montpellier
Trial primary completion date: May 2015 --> Feb 2014 N=200 --> 101 | Recruiting --> Terminated | Trial primary completion date: Jun 2012 --> Jun 2011; Results obtained are sufficient for a publication.
- Trial suspension: RespiStimALS: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation (clinicaltrials.gov) - Jul 21, 2015
P3, N=74, Suspended, Sponsor: Assistance Publique - H
N=200 --> 101 | Recruiting --> Terminated | Trial primary completion date: Jun 2012 --> Jun 2011; Results obtained are sufficient for a publication. Recruiting --> Suspended
- || Betaseron (IFN-β-1b) / Bayer
Trial primary completion date, Adherence: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=450, Recruiting, Sponsor: Bayer
Recruiting --> Suspended Trial primary completion date: Mar 2016 --> Jun 2016
- | ceralifimod (ONO 4641) / Ono Pharma
Trial termination, Trial primary completion date: DreaMS: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jul 17, 2015
P2, N=343, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Dec 2014; Merck has decided to not pursue phase 3 development of ceralifimod (ONO-4641). The decision was not related to any safety and efficacy findings
- ATX-MS-1467 / Apitope
Enrollment closed: ATX-MS-1467 in Multiple Sclerosis (clinicaltrials.gov) - Jul 14, 2015
P2, N=17, Active, not recruiting, Sponsor: Merck KGaA
The decision was not related to any safety and efficacy findings Recruiting --> Active, not recruiting
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Enrollment change, Trial primary completion date: STRIVE: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=229, Active, not recruiting, Sponsor: Biogen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=300 --> 229 | Trial primary completion date: Dec 2016 --> Nov 2018
- | minocycline / Generic mfg.
Trial completion: MinoCIS: Minocycline in Clinically Isolated Syndromes (CIS) (clinicaltrials.gov) - Jul 14, 2015
P3, N=140, Completed, Sponsor: Dr. Luanne Metz
Recruiting --> Active, not recruiting | N=300 --> 229 | Trial primary completion date: Dec 2016 --> Nov 2018 Active, not recruiting --> Completed
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Enrollment change, Trial primary completion date: Ireland Natalizumab (TYSABRI) Observational Program (clinicaltrials.gov) - Jul 13, 2015
P=N/A, N=191, Active, not recruiting, Sponsor: Biogen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=1000 --> 191 | Trial primary completion date: Sep 2017 --> Dec 2017
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Enrollment change: STRATIFY-2: JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (clinicaltrials.gov) - Jul 13, 2015
P=N/A, N=36065, Active, not recruiting, Sponsor: Biogen
Recruiting --> Active, not recruiting | N=1000 --> 191 | Trial primary completion date: Sep 2017 --> Dec 2017 Enrolling by invitation --> Active, not recruiting | N=8000 --> 36065
- ||||||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jul 13, 2015
P3, N=260, Completed, Sponsor: EMD Serono
Enrolling by invitation --> Active, not recruiting | N=8000 --> 36065 No longer recruiting --> Completed
- Trial initiation date, Trial primary completion date, Immunomodulating: IMODALS: Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 (clinicaltrials.gov) - Jul 13, 2015
P2, N=36, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
No longer recruiting --> Completed Initiation date: Jun 2015 --> Sep 2015 | Trial primary completion date: Dec 2015 --> Apr 2016
- ||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 13, 2015
P3, N=185, Completed, Sponsor: Allergan
Initiation date: Jun 2015 --> Sep 2015 | Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Completed
- Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Trial primary completion date: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jul 9, 2015
P2, N=180, Active, not recruiting, Sponsor: Opexa Therapeutics, Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Aug 2016
- Enrollment change: P300 Brain Computer Interface Keyboard to Operate Assistive Technology (clinicaltrials.gov) - Jul 9, 2015
P1/2, N=29, Completed, Sponsor: University of Michigan
Trial primary completion date: Dec 2015 --> Aug 2016 N=72 --> 29
- minocycline / Generic mfg.
Trial primary completion date: MinoCIS: Minocycline in Clinically Isolated Syndromes (CIS) (clinicaltrials.gov) - Jul 9, 2015
P3, N=154, Active, not recruiting, Sponsor: Dr. Luanne Metz
N=72 --> 29 Trial primary completion date: Mar 2015 --> Dec 2014
- Tysabri (natalizumab) / Biogen, Royalty
Enrollment change, Trial termination, Trial primary completion date: SIMPLIFY: Natalizumab Subcutaneous Immunogenicity and Safety Study (clinicaltrials.gov) - Jul 8, 2015
P2, N=2, Terminated, Sponsor: Biogen
Trial primary completion date: Mar 2015 --> Dec 2014 N=113 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Nov 2016; Sponsor's decision.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Trial primary completion date, IO biomarker, Metastases: Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma (clinicaltrials.gov) - Jul 6, 2015
P2, N=50, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=113 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Nov 2016; Sponsor's decision. Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Oct 2014
- Trial suspension, Trial primary completion date: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Jul 2, 2015
P=N/A, N=15, Suspended, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Oct 2014 Recruiting --> Suspended | Trial primary completion date: Jun 2015 --> Jun 2016
- Orencia (abatacept) / BMS
Trial completion: ACCLAIM: A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (clinicaltrials.gov) - Jul 2, 2015
P2, N=65, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Suspended | Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed
- ||||||| Trial completion: A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis (clinicaltrials.gov) - Jul 2, 2015
P3, N=87, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| dalfampridine / Generic mfg.
Enrollment closed, Enrollment change: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (clinicaltrials.gov) - Jun 30, 2015
P3, N=101, Active, not recruiting, Sponsor: Biogen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=128 --> 101
- Trial primary completion date: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Jun 29, 2015
P2, N=80, Recruiting, Sponsor: Academic MS Center Limburg
Recruiting --> Active, not recruiting | N=128 --> 101 Trial primary completion date: Mar 2015 --> Jul 2016
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment change: ESCALATE: Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (clinicaltrials.gov) - Jun 29, 2015
P4, N=130, Recruiting, Sponsor: Biogen
Trial primary completion date: Mar 2015 --> Jul 2016 N=200 --> 130
- ||| glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Enrollment open, Trial initiation date, Patient reported outcomes: Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=240, Recruiting, Sponsor: Biogen
N=200 --> 130 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015
- | Farydak (panobinostat) / Secura Bio
Enrollment closed: A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 29, 2015
P2, N=25, Active, not recruiting, Sponsor: Kristie Blum
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Jun 26, 2015
P3, N=600, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Dec 2015